Resona Asset Management Co. Ltd. Raises Position in Edwards Lifesciences Corporation $EW

Resona Asset Management Co. Ltd. increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 3.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 202,399 shares of the medical research company’s stock after purchasing an additional 7,686 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $15,830,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Atlantic Union Bankshares Corp purchased a new stake in Edwards Lifesciences in the second quarter worth $40,000. Moors & Cabot Inc. grew its stake in shares of Edwards Lifesciences by 0.4% during the 2nd quarter. Moors & Cabot Inc. now owns 53,749 shares of the medical research company’s stock worth $4,204,000 after acquiring an additional 225 shares during the period. Cassaday & Co Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 2nd quarter worth about $202,000. NewSquare Capital LLC raised its stake in Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the period. Finally, Prosperity Consulting Group LLC lifted its holdings in Edwards Lifesciences by 3.2% during the second quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock valued at $337,000 after purchasing an additional 132 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 1.1%

Edwards Lifesciences stock opened at $83.37 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $87.09. The stock has a market cap of $48.95 billion, a P/E ratio of 12.00, a PEG ratio of 3.97 and a beta of 1.03. The firm’s fifty day moving average price is $77.78 and its 200-day moving average price is $77.31.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s revenue was up 14.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EW. Wells Fargo & Company lifted their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research note on Thursday, August 7th. Oppenheimer downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a report on Friday, July 25th. Finally, Mizuho raised their price target on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus price target of $91.39.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.